EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis

Sarah Bayrakdarian, Caroline Hircock, Henry C Y Wong, Liying Zhang, Keyue Ding, Irene Karam, François Gallant, Eileen Rakovitch, William Tran, Hany Soliman, Eric Leung, Danny Vesprini und 7 weitere

Breast Cancer Research and Treatment · 2026-06 · 217 (2)

DOI: 10.1007/s10549-026-07987-5 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Breast Cancer Research and Treatment, online erschienen am 04.06.2026. Verfasst von Sarah Bayrakdarian und 18 weiteren Autor:innen. Beteiligte Einrichtung: Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada. Hauptthemen laut MEDLINE: Radiodermatitis, Patient Reported Outcome Measures, Breast Neoplasms, Standard of Care. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This study aims to evaluate the long-term skin-related patient-reported outcomes (PROs) of a randomized controlled trial (RCT) comparing Mepitel Film (MF) to standard of care (SOC) for the prevention of acute radiation dermatitis (ARD) in breast cancer patients undergoing radiation therapy (RT). METHODS: Patients were contacted via telephone at 6 months, 12 months, and 24 months post-RT to complete the Skin Symptom Assessment (SSA) and Radiation-induced Skin Reaction Assessment Scale (RISRAS). SSA and RISRAS scores at follow-up visits were compared to baseline using a generalized estimation equation with Poisson distribution and log link function. To account for multiple testing, the Bonferroni-adjusted p-value of < 0.001 was considered statistically significant. RESULTS: From April 2020 to August 2024, 376 patients were included in the modified intention-to-treat analysis and followed at the pre-specified time points. When comparing MF and SOC, no significant differences were captured longitudinally regardless of the severity of ARD (Common Terminology Criteria for Adverse Events grade [G] 0-1 versus G2-3). Comparing to the baseline scores, patients reported worse pruritis at 6 months and pigmentation at 6 months, 12 months, and 24 months (p < 0.001) for the SSA. For the RISRAS, tenderness/discomfort/pain, itchiness and burning sensation were worse at 6 months (p < 0.001), but only itchiness was worse at 12 and 24 months (p = 0.0007, p < 0.001, respectively) compared to baseline. In the subgroup analysis of patients based on the severity of ARD, pigmentation was worse at all follow-up visits (p < 0.001) in both G0-1 and G2-3 cohorts. CONCLUSION: PROs returned to baseline at 6 months to 2 years after RT, except pigmentation and pruritis that persist regardless of the severity of ARD, necessitating confirmation with physical signs and further research to understand the pathophysiology of these chronic symptoms to guide preventative strategies. No long-term issues were identified in patients treated with MF, confirming it as a safe and effective strategy for the prevention of ARD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiodermatitisPatient Reported Outcome MeasuresBreast NeoplasmsStandard of CareHumansFemaleMiddle AgedAgedAdultQuality of Life

Stichwörter der Autor:innen

Breast cancerChronic radiation dermatitisPatient-reported outcomesPreventionRadiation treatment

Autor:innen und Institutionen

  • Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
  • Department of Oncology, Princess Margaret Hospital, Kowloon West Cluster, Hospital Authority, Hong Kong, SAR, China.
  • MacroStat Inc, Toronto, ON, Canada.
  • Canadian Cancer Trials Division, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada.
  • Faculty of Science, McMaster University, Hamilton, ON, Canada.
  • Department of Radiation Oncology, Health Sciences North, Sudbury, ON, Canada.

Zitieren

APA

Bayrakdarian, S., Hircock, C., Wong, H. C. Y., Zhang, L., Ding, K., Karam, I., Gallant, F., Rakovitch, E., Tran, W., Soliman, H., Leung, E., Vesprini, D., Szumacher, E., Chen, H., Donovan, E., Lam, J., Spadafora, S., Carothers, K., & Chow, E. (2026). Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis. Breast Cancer Research and Treatment, 217(2). https://doi.org/10.1007/s10549-026-07987-5

Vancouver

Bayrakdarian S, Hircock C, Wong HCY, Zhang L, Ding K, Karam I, et al. Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis. Breast Cancer Research and Treatment. 2026;217(2). doi:10.1007/s10549-026-07987-5

BibTeX
@article{Bayrakdarian2026,
  author = {Bayrakdarian, Sarah and Hircock, Caroline and Wong, Henry C Y and Zhang, Liying and Ding, Keyue and Karam, Irene and Gallant, François and Rakovitch, Eileen and Tran, William and Soliman, Hany and Leung, Eric and Vesprini, Danny and Szumacher, Ewa and Chen, Hanbo and Donovan, Elysia and Lam, Jacqueline and Spadafora, Silvana and Carothers, Katherine and Chow, Edward},
  title = {Long-term patient-reported outcomes in a randomized controlled trial of Mepitel Film versus standard of care for the prevention of acute breast radiation dermatitis},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  volume = {217},
  number = {2},
  doi = {10.1007/s10549-026-07987-5}
}
Kostenlos starten →